Osel, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1996-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.oselinc.com
CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer
Phase 1
Recruiting
- Conditions
- Metastatic Renal Cell CarcinomaAdvanced Clear Cell Renal Cell CarcinomaAdvanced Sarcomatoid Renal Cell CarcinomaMetastatic Sarcomatoid Renal Cell CarcinomaAdvanced Renal Cell CarcinomaMetastatic Clear Cell Renal Cell CarcinomaStage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone ScanBiological: CBM588 CapsulesProcedure: Computed TomographyBiological: IpilimumabProcedure: Magnetic Resonance ImagingBiological: Nivolumab
- First Posted Date
- 2024-05-03
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Osel, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT06399419
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Safety and Clinical Effectiveness of Oral Probiotic MIYA-BM to Prevent Recurrent Clostridium Difficile Infections
Phase 2
Withdrawn
- Conditions
- Clostridium Difficile Infection
- Interventions
- Drug: Placebo Fine Granules (without CBM588)Drug: MIYA-BM Fine Granules (CBM588)
- First Posted Date
- 2010-03-01
- Last Posted Date
- 2013-11-11
- Lead Sponsor
- Osel, Inc.
- Registration Number
- NCT01077245
Safety and Efficacy Study of Lactobacillus Administered Vaginally in Women With Bacterial Vaginosis
Phase 2
Completed
- Conditions
- Bacterial Vaginosis
- Interventions
- Drug: Placebo control substance
- First Posted Date
- 2008-03-14
- Last Posted Date
- 2009-07-10
- Lead Sponsor
- Osel, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00635622
- Locations
- 🇺🇸
San Francisco General Hospital (SFGH), University of California, San Francisco (UCSF), San Francisco, California, United States
Safety Study of Lactobacillus Administered Vaginally to Healthy Women
Phase 1
Completed
- Conditions
- Bacterial Vaginosis
- Interventions
- Other: Low dose Placebo applicatorBiological: High dose LACTIN-V applicatorBiological: Medium dose LACTIN-V applicatorOther: Medium dose PlaceboBiological: Low dose LACTIN-V applicatorOther: High dose Placebo applicator
- First Posted Date
- 2007-10-01
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- Osel, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT00537576
- Locations
- 🇺🇸
San Francisco General Hospital, San Francisco, California, United States
© Copyright 2025. All Rights Reserved by MedPath